New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
08:20 EDTRDHLRedHill Biopharma announces commencement of bioavailability study of RHB-103
RedHill Biopharma together with IntelGenx announced the commencement of a comparative bioavailability clinical study comparing RHB-103 to the European reference drug. The study is intended to support the planned submission of a European Marketing Authorization Application for RHB-103, a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. Results of the bioavailability study are anticipated by June.
News For RDHL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
07:04 EDTRDHLRedHill Biopharma receives authorization in Australia, New Zealand for study
Subscribe for More Information
July 1, 2015
07:09 EDTRDHLRedHill Biopharma receives notice of allowance for two U.S. patents for RHB-104
RedHill Biopharma announced that it has received two notices of allowance from the United States Patent and Trademark Office regarding its patent application numbers 13/722,395 and 14/271,758 covering RHB-104. RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties, currently undergoing a first Phase III study for Crohn's disease and a Phase IIa study for multiple sclerosis.
June 29, 2015
07:08 EDTRDHLRedHill Biopharma initiates Phase I/II study of ABC294640
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use